Pharmaceuticals APAC

APAC Neglected Tropical Disease Drugs Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

APAC Neglected Tropical Disease Drugs Market Industry Trends and Forecast to 2034: Segmented by (Disease, Buyer, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

APAC · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $235.4 Mn Placeholder estimate
Estimate 2025 $250.0 Mn 22.7% of the global market
Projected 2034 $429.7 Mn 71.8% Adds $179.6 Mn over 9 forecast years
CAGR 2025–2034 6.2% Faster than 16% of 186 Pharmaceuticals markets here
Key players 5
  • APAC is 22.68% of the global market.
  • Among regions, the largest is North America at $563.7 Mn.
  • Fastest growing: APAC (this report) at 6.2% a year.
  • APAC ranks 2nd of 6 by size among regions.

Market size projection

APAC

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$179.6 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Neglected Tropical Disease Drugs Market market size by year, APAC
YearMarket sizeChange that yearSince 2025
2024 (estimate) $235.4 Mn — —
2025 (base) $250.0 Mn +$14.6 Mn —
2026 (forecast) $265.5 Mn +$15.5 Mn +6.2%
2027 (forecast) $282.0 Mn +$16.5 Mn +12.8%
2028 (forecast) $299.5 Mn +$17.5 Mn +19.8%
2029 (forecast) $318.1 Mn +$18.6 Mn +27.2%
2030 (forecast) $337.8 Mn +$19.7 Mn +35.1%
2031 (forecast) $358.7 Mn +$20.9 Mn +43.5%
2032 (forecast) $381.0 Mn +$22.2 Mn +52.4%
2033 (forecast) $404.6 Mn +$23.6 Mn +61.8%
2034 (forecast) $429.7 Mn +$25.1 Mn +71.8%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

APAC Neglected Tropical Disease Drugs Market Analysis at a glance
Market size, 2025$250.0 Mn placeholder estimate
Forecast, 2034$429.7 Mn placeholder estimate
Growth (CAGR), 2025–20346.2% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
Also calledNeglected Tropical Disease Treatment
SegmentsDisease and buyer (see all)
Key playersMerck & Co., Inc., GSK PLC, Sanofi, Novartis AG, DNDi (see all)
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The APAC Neglected Tropical Disease Drugs Market Analysis Executive Summary

Neglected tropical disease drugs treat diseases such as river blindness, sleeping sickness and parasitic worms that mainly affect poor communities.

Key segments of the neglected Tropical Disease Drugs market include disease (Helminth Infections, Leishmaniasis and Chagas Disease) and buyer (Donation Programs, Governments and NGOs).

Bar chart: Asia Pacific Neglected Tropical Disease Drugs market size, 2024–2034, placeholder estimates. $235.4 Mn in 2024, $250.0 Mn in 2025 and $429.7 Mn in 2034, 6.2% CAGR.
Asia Pacific Neglected Tropical Disease Drugs market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

APAC Neglected Tropical Disease Drugs Market Dynamics

Market Growth Drivers

Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the neglected Tropical Disease Drugs market.

Opportunity

New vaccines, rapid tests and public-private funding for neglected diseases give the neglected Tropical Disease Drugs market room to grow, especially in Asia, Africa and Latin America.

Market Restraints

Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the neglected Tropical Disease Drugs market.

Competitive Landscape for Neglected Tropical Disease Drugs Market in APAC

The neglected Tropical Disease Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Neglected Tropical Disease Drugs Market in APAC

Neglected Tropical Disease Drugs in APAC: rules and payment

In some of the countries we cover here, medicines are approved by TGA (Australia)⁠[1], NMPA (China)⁠[2], Drug Office (Hong Kong)⁠[3], CDSCO (India)⁠[4], PMDA (Japan)⁠[5], NPRA (Malaysia)⁠[6], Medsafe (New Zealand)⁠[7], FDA Philippines (Philippines)⁠[8], HSA (Singapore)⁠[9], Thai FDA (Thailand)⁠[10], BPOM (Indonesia)⁠[11], DRAP (Pakistan)⁠[12], MFDS (South Korea)⁠[13] and Drug Administration of Vietnam (Vietnam)⁠[14]. How care is paid for in some of these countries: Medicare and the PBS (Australia)⁠[15], basic medical insurance (China)⁠[16], the Hospital Authority (Hong Kong)⁠[17], Ayushman Bharat PM-JAY (India)⁠[18], public health insurance (Japan)⁠[19], subsidised public care (Malaysia)⁠[20], Pharmac (New Zealand)⁠[21], PhilHealth (Philippines)⁠[22], MediShield Life (Singapore)⁠[23], the Universal Coverage Scheme (Thailand)⁠[24], JKN (BPJS Kesehatan) (Indonesia)⁠[25], out of pocket and Sehat Sahulat (Pakistan)⁠[26], National Health Insurance (South Korea)⁠[27] and social health insurance (Vietnam)⁠[28].

[1] Therapeutic Goods Administration. Checked 14 Nov 2026.

[2] National Medical Products Administration. Checked 14 Nov 2026.

[3] Drug Office, Department of Health. Checked 14 Nov 2026.

[4] Central Drugs Standard Control Organisation. Checked 14 Nov 2026.

[5] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.

[6] National Pharmaceutical Regulatory Agency. Checked 14 Nov 2026.

[7] Medsafe. Checked 14 Nov 2026.

[8] Food and Drug Administration Philippines. Checked 14 Nov 2026.

[9] Health Sciences Authority. Checked 14 Nov 2026.

[10] Thai Food and Drug Administration. Checked 14 Nov 2026.

[11] National Agency of Drug and Food Control (BPOM). Checked 19 Nov 2026.

[12] Drug Regulatory Authority of Pakistan (DRAP). Checked 19 Nov 2026.

[13] Ministry of Food and Drug Safety. Checked 19 Nov 2026.

[14] Drug Administration of Vietnam. Checked 19 Nov 2026.

[15] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.

[16] National Healthcare Security Administration. Checked 14 Nov 2026.

[17] Hospital Authority. Checked 14 Nov 2026.

[18] National Health Authority (PM-JAY). Checked 14 Nov 2026.

[19] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.

[20] Ministry of Health Malaysia. Checked 14 Nov 2026.

[21] Pharmac. Checked 14 Nov 2026.

[22] PhilHealth. Checked 14 Nov 2026.

[23] CPF Board, MediShield Life. Checked 14 Nov 2026.

[24] National Health Security Office. Checked 14 Nov 2026.

[25] BPJS Kesehatan. Checked 19 Nov 2026.

[26] Ministry of National Health Services, Regulations and Coordination. Checked 19 Nov 2026.

[27] Health Insurance Review and Assessment Service (HIRA). Checked 19 Nov 2026.

[28] Vietnam Social Security. Checked 19 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for neglected Tropical Disease Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in APAC.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Neglected Tropical Disease Drugs right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Neglected Tropical Disease Drugs in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Neglected Tropical Disease Drugs market in Asia Pacific?
Placeholder estimate: about $250.0 Mn in 2025, rising to about $429.7 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Neglected Tropical Disease Drugs market in Asia Pacific growing?
Placeholder estimate: about 6.2% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Neglected Tropical Disease Drugs market report cover?
The report splits the market by disease (Helminth Infections, Leishmaniasis, Chagas Disease, Sleeping Sickness) and buyer (Donation Programs, Governments, NGOs).
Who are the key players in the Neglected Tropical Disease Drugs market?
Key players include Merck & Co., Inc., GSK PLC, Sanofi, Novartis AG and DNDi.
What is driving the Neglected Tropical Disease Drugs market?
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the neglected Tropical Disease Drugs market.
How much research is published on Neglected Tropical Disease Drugs?
PubMed lists 1,526 papers on Neglected Tropical Disease Drugs added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in APAC

See all

Related on infectious diseases

See the topic